1 / 23

Clinical Chemistry of Parathyroid disorders

Clinical Chemistry of Parathyroid disorders. BONE. H 2 O. Inorganic Ca-hydroxyapatit e. Ca 2+ 10-x (H 3 O + ) 2x (PO 4 3- ) 6 (OH - ) 2. Organic (osteoid). osteocalcin osteonectin osteopontin. Proteoglycans lipids. collagen (type I). 88%. 12%. CELLS IN BONE. 1. Osteoblast

butlerw
Download Presentation

Clinical Chemistry of Parathyroid disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Chemistry of Parathyroid disorders

  2. BONE H2O Inorganic Ca-hydroxyapatite Ca 2+10-x (H3O+)2x(PO4 3-)6(OH-)2 Organic (osteoid) osteocalcin osteonectin osteopontin Proteoglycans lipids collagen (type I) 88% 12%

  3. CELLS IN BONE • 1. Osteoblast • - production of organic matrix (osteoid) • - potentiate and control mineralisation • - potentiate production of alkaline phosphatase • 2. Osteocyte • - connection with extracellular fluid • - regulation of Ca and Pi movement between bone and extracellular fluid • 3. Osteoclast • - polynuclear specific macrophages • - bone resorption

  4. Ca 2+ PROTEIN (albumin) Ca 2+ Anion Ca 2+ Ca 2+ Ca 2+ - - - - - - - - - - - - - - Anions HCO3- H2PO4- HPO4-2 Citrate Lactate - - - - Complexed calcium 7% Protein bound calcium 46% Free calcium 47% Total calcium (2.1-2.6 mmol/l)

  5. Hormones regulating plasma calcium concentration • Parathyroid hormone (PTH) • parathyroid glands • Calcitriol - 1-25 DHCC (active vitamin D) • Formed after hydroxylation!(liver, renal) • Calcitonin (thyreoidea C cells) • Its physiological function is not well characterized

  6. A parathyroid hormone (PTH) • Polypeptide (84 aminoacids) • Product of chief cells of parathyroid glands • N-terminal 34 AA fragment and intact PTH • are biologically active • increase of serum Ca2+ • decrease of serum phosphate

  7. Half life: 3-4 min Half life: 2-3 hours

  8. Target organs for PTH • Bone: • Ca and Pi resorption by osteoclasts • Kidney • tubular Ca reabsorption • tubular Mg reabsorption • tubular P reabsorption • tubular HCO3 reabsorption • Intestine • 1-25 DHCC production in kidneys

  9. PTH regulation and mechanism of action Stimulatory effects: Se Ca 2+ Mild hypomagnesaemia Inhibition: Se Ca 2+ Severe hypomagnesaemia Calcitriol PTH release PTH binding to the target cell receptors (Mg dependent) Adenylate cyclase cAMP Ca 2+ cellular influx to the target cells

  10. Abnormal functions of parathyroid glands • Hyperparathyroidism • Primary • Secondary (PTH increase is physiological response) • Tertiary (autonome PTH secretion) • Hypoparathyroidism • Congenital/acquired • Pseudohypoparathyroidism

  11. Secondary hyperparathyreoidism A/ With osteomalacia or rickets a. Decrease of Ca and vitamin D uptake or absorptionCa, vitamin D deficient diet, Steatorrhoea or malabsorption b. Defect in production of active vitamin D Chronic renal failure Chronic hepatopathia lack of alpha hydroxylation c.Increased inactivation of vitamin D anticonvulsive therapy d. Lack of 25 HCC transport protein e. D vitamin receptor defect B/ Without osteomalacia and rickets a. acute pancreatitis b. neonatal hypocalcaemia

  12. Secondary Tertiary Primary Se Ca2+ Phosphate Alkaline phosphatase PTH Typical biochemical features of hyperparathyroidism or N or or N or N or

  13. Parathyroid hormone-related peptide • It is elevated in 50-90% of patients with • hypercalcemia associated with malignancy • Its gene on chr 12 (PTH gene on chr 11) • 3 isoforms • N terminal end shows homology to PTH • Can bind to PTH receptors and mimic its • biological action

  14. Serum calcium Normal or decreased Increased PTH PTH Increased Increased Normal Decreased Secondary HPT Primary HPT Tumor hypercalcemia Creatinine Other causes of Hyper- calcemia Increased Normal Other causes of secondary HPT Renal disease

  15. Hypoparathyreoidism Congenital e.g. DiGeorge synd. (immunodeficiency + thymic aplasia) - Pseudohypoparathyroidism Acquired 1/ Operation a. total or partial thyroidectomy b. laryngectomy c. parathyroidectomy 2/ Autoimmune disorder 3/ Haemochromatosis 4/ infiltrative states

  16. Pseudohypoparathyroidism Hereditary disorders, plasma PTH are elevated, but superficially resembles hypoparathyroidism Type 1 Activation of adenyl cyclase is defective and cyclic AMP is not formed Rounded face and skeletal abnormalities, learning difficulties Type 2 cAMP is formed, but the responses to it are blocked Differentiation: Urinary cAMP after PTH: elevated in type 2

  17. Typical biochemical features of hypoparathyroidism True Pseudo Se Ca2+ Phosphate Alkaline phosphatase N N PTH

  18. Calcitriol • Derived from Vitamin D by successive hydroxylation UV 7-dehydrocholesterol Cholecalciferol Liver 25-(OH)-Cholecalciferol (Calcidiol) Kidney 1,25-(OH)2- Cholecalciferol (Calcitriol) 24,25-(OH)2- Cholecalciferol

  19. Regulation of hydroxylation in the kidney Synthesis of a Ca2+-binding protein (calbindin D) Longer term stimulatory effect:GH, prolactin, estrogen

  20. Calcitriol • Effects: • Ca and P absorption from intestine • Ca and P resorption from bones by osteoclasts • Receptors of calcitriol in other tissues • Cellular differentiation (normal and malignant cells) • Immunomodulatory effect : • Stimulation of production of cytokines

  21. Calcitonin • Polypeptide hormone • Thyreoid C cells • Its physiological function is unknown / under investigation • after total thyreoidectomy no clinical symptoms! • calcium homeostasis is normal • Its level is elevated • pregnancy • lactation • Has been detected • gut • CNS (neurotransmitter) • Experimentally • inhibit osteoclast activity, thus bone resorption • Clinical significance • medullary carcinoma, small cell cc

More Related